RubrYc Therapeutics Announces Research Collaboration and Licensing Option Agreement with Zai Labs
Saturday, April 17, 2021
RubrYc Therapeutics, Inc., a company that manufactures preclinical biotherapeutic products and develops epitope-selective therapies,announced that it has entered into a research collaboration and licensing option agreement with Zai Labs. on the use of RubrYc's Meso-scale Engineered Molecules (MEMs) platform to identify monoclonal antibodies with enhanced biological function for previously unpublished oncology purposes.
Under the agreement, RubrYc and Zai Labs will work together to identify product candidates using the RubrYc discovery engine. The discovery engine uses machine learning and uses structural data to identify antibodies that bind to subdominant epitopes and show differentiated activity. The license option grants Zai Labs the exclusive global right to develop and commercially deploy the product (s) discovered in the research collaboration.
RubrYc Therapeutics, Inc. is entitled to a prepayment amount and, for each drug candidate, to meet any additional fees and license fees for achieving net research, development and commercial launch milestones after net sales of each product globally. The financial terms of the agreement were not disclosed.
Dr. Isaac Bright, CEO of RubrYc, said: “We are very pleased that Zai Labs has selected the RubrYc discovery engine for its work to identify biotherapeutic agents for the highly challenging oncological diseases. We look forward to working with Zai Labs to accelerate their research to identify epitope-specific antibodies with differentiated mechanisms of action. Zai Labs' oncology expertise complements our efforts to provide new breakthrough therapies to patients in need. ”
